Doctors track hidden joint damage in hemophilia patients on new drug
NCT ID NCT07420348
Summary
This study aims to understand how well the drug emicizumab protects joints from hidden damage in people with hemophilia A. Researchers will follow about 70 patients for two years, using ultrasound scans to check for early signs of joint problems in elbows, knees, and ankles that appear healthy at the start. The study is observational, meaning it only monitors patients on their standard emicizumab treatment without changing their care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universidad de Oviedo
Oviedo, Principality of Asturias, 33006, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.